Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 5Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1871Triple Negative Breast Neoplasms 126Neoplasms 74Ovarian Neoplasms 56Neoplasm Metastasis 55Colorectal Neoplasms 54Prostatic Neoplasms 53Lung Neoplasms 51Stomach Neoplasms 45Pancreatic Neoplasms 43Motor Activity 41Colonic Neoplasms 41Lymphedema 35Breast Cancer Female 32Advanced Breast Cancer 32Carcinoma, Non-Small-Cell Lung 31Endometrial Neoplasms 28Melanoma 27Breast Diseases 26Head and Neck Neoplasms 25Cardiotoxicity 25HER2-positive Breast Cancer 22Uterine Cervical Neoplasms 21Brain Neoplasms 21Breast Cancer Lymphedema 20Pain 19Fatigue 19Esophageal Neoplasms 19Breast Neoplasms, Male 19Urinary Bladder Neoplasms 18

Interventions

pyrotinib 1Vinorelbine 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × HER2 Positive Breast Cancer × Breast × Clear all
NCT03947242 2019-05-15

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Henan Cancer Hospital

Phase NA Unknown
48 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡